title: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
abstract: OBJECTIVE
  To investigate the procedure, feasibility and effects of laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers.
  
  
  METHODS
  From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding. Each patient underwent CHIPC three times after laparoscope-assisted perfusion catheters placing. The first session was completed in operative room under general anesthesia, 5% glucose solution was selected as perfusion liquid, and 1500 mg 5-fluorouracil (5-FU) and 200 mg oxaliplatin were added in the perfusion solution. The second and third sessions were performed in intensive care unit, 0.9% sodium chloride solution was selected as perfusion liquid, and 1500 mg 5-FU was added in the perfusion solution alone. CHIPC was performed for 90 min at a velocity of 450-600 mL/min and an inflow temperature of 43 +/- 0.2 degrees C.
  
  
  RESULTS
  The intraoperative course was uneventful in all cases, and the mean operative period for laparoscope-assisted perfusion catheters placing was 80 min for each case. No postoperative deaths or complications related to laparoscope-assisted CHIPC occurred in this study. Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients. During the follow-up, 13 patients died 2-9 mo after CHIPC, with a median survival time of 5 mo. Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment. Three patients who are still alive today survived 4, 6 and 7 mo, respectively. The Karnofsky marks of patients (50-90) increased significantly (P < 0.01) and the general status improved after CHIPC. Thus satisfactory clinical efficacy has been achieved in these patients treated by laparoscopic CHIPC.
  
  
  CONCLUSIONS
  Laparoscope-assisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.
authors.affiliation: Department of Abdominal Surgery (Section 2), Cancer Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Ming-Chen
authors.initials: MC
authors.lastname: Ba
authors.forename: Shu-Zhong
authors.initials: SZ
authors.lastname: Cui
authors.forename: Sheng-Qu
authors.initials: SQ
authors.lastname: Lin
authors.forename: Yun-Qiang
authors.initials: YQ
authors.lastname: Tang
authors.forename: Yin-Bing
authors.initials: YB
authors.lastname: Wu
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Xiang-Liang
authors.initials: XL
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D001201:Ascites / Q000188:drug therapy / Q000473:pathology*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D010477:Perfusion; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil
references.citation: J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5
references.pmid: 17481516
references.citation: Eur J Surg Oncol. 2006 Aug;32(6):682-5
references.pmid: 16631341
references.citation: Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x
references.pmid: 17606199
references.citation: Gynecol Oncol. 2005 Nov;99(2):358-61
references.pmid: 16112182
references.citation: Eur J Surg Oncol. 2005 Jun;31(5):540-3
references.pmid: 15922890
references.citation: Ann Surg Oncol. 2007 Nov;14(11):3274-82
references.pmid: 17653591
references.citation: J Gastrointest Surg. 2006 Jul-Aug;10(7):1038-43
references.pmid: 16843875
references.citation: In Vivo. 2009 Jan-Feb;23(1):187-90
references.pmid: 19368148
references.citation: J Surg Oncol. 2003 Jul;83(3):147-53
references.pmid: 12827682
references.citation: Ann Surg Oncol. 2008 Feb;15(2):542-6
references.pmid: 17929098
references.citation: Ann Surg Oncol. 2008 Jan;15(1):339-44
references.pmid: 17943387
references.citation: Surg Laparosc Endosc Percutan Tech. 2008 Aug;18(4):426-8
references.pmid: 18716551
references.citation: Eur J Surg Oncol. 2008 Feb;34(2):154-8
references.pmid: 17640844
references.citation: Suppl Tumori. 2005 May-Jun;4(3):S122-3
references.pmid: 16437944
references.citation: Eur J Surg Oncol. 2006 Aug;32(6):625-7
references.pmid: 16822641
references.citation: Cancer. 2006 Mar 1;106(5):1144-53
references.pmid: 16456817
references.citation: World J Gastroenterol. 2008 Feb 28;14(8):1159-66
references.pmid: 18300340